Popular GLP-1 weight-loss drugs linked to lower risks of addiction and overdose
A recent study suggests that GLP-1 weight-loss drugs may reduce the risks of addiction and overdose among users. Researchers found that these medications, originally developed for diabetes management, are linked to lower rates of substance use disorders and serious health outcomes. The findings indicate that GLP-1 drugs could play a significant role in both preventing and treating addiction across various substances.
- ▪The study analyzed health records from over 600,000 U.S. veterans.
- ▪Participants taking GLP-1 medications had a 14% lower risk of developing substance use disorders.
- ▪Among those with existing substance use disorders, GLP-1 users experienced a 40% reduction in overdoses.
Opening excerpt (first ~120 words) tap to expand
Science News from research organizations Popular GLP-1 weight-loss drugs linked to lower risks of addiction and overdose Popular weight-loss drugs may also help silence the cravings behind addiction, reducing risks across alcohol, nicotine, opioids, and other substances. Date: June 3, 2026 Source: WashU Medicine Summary: A massive study of more than 600,000 U.S. veterans suggests that popular GLP-1 drugs such as semaglutide may do far more than help with diabetes and weight loss—they could also fight addiction itself.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at ScienceDaily.
Discussion
0 commentsMore from ScienceDaily
